Thermo Fisher Scientific increased availability of COVID-19 testing with sample collection kit from Everlywell
On Oct. 19, 2020, Thermo Fisher Scientific announced it had received an expansion of its Emergency Use Authorization…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
Just – Evotec Biologics received grant to enable an antibody product for the prevention of COVID-19
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
Racial differences in Alzheimer’s research focus of $15 million grant
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
AMSP partnered with bioMerieux to facilitate supply of high-quality COVID-19 diagnostics
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
Biotechnology | COVID-19 | Disease | Life Science News | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
Biotechnology | COVID-19 | Diagnostics | FDA
Abbott’s released ID NOW COVID-19 interim clinical study results to provide facts on clinical performance
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
Mateon announced first patient enrolled in ARTI-19 multicenter interventional study of Artshield against COVID-19
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
Sonic Healthcare enhanced test offerings with launch of multiplex assay for COVID-19 and flu
On Oct. 7, 2020, Sonic Healthcare USA announced that it had launched a multiplex RT-PCR assay that combined…
Hologic Panther Platform and HIV-1 Quant assay used in ‘HIV Cure’ research
On Oct. 6, 2020, Hologic announced that two studies in the Journal of Clinical Microbiology demonstrated the utility…
Broad and Brigham and Women’s Hospital launched COVID-19 surveillance study
On Oct. 6, 2020, clinicians and researchers from Brigham and Women’s Hospital, the Broad Institute of MIT and…
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19
On Oct. 2, 2020, Quidel announced that it had received Emergency Use Authorization from the FDA to market…
Johnson & Johnson completed acquisition of Momenta Pharmaceuticals for $65 billion
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
Neandertal gene variant increases risk of severe Covid-19
On Sept. 30, 2020, researchers at the Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary…
Sorrento Therapeutics and ViralClear entered agreement to explore combination antibody plus antiviral therapy against COVID-19
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
Bio-Techne announced opening of GMP manufacturing facility in Twin Cities
On Sept. 30, 2020, Bio-Techne announced the opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing…
Quest Diagnostics launched three new combined COVID-19 and respiratory virus tests
On Sept. 30, 2020, Quest Diagnostics announced three different test options for healthcare providers across the U.S.to aid…
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial…
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
ViroVax licensed adjuvant to be used in India’s first COVID-19 vaccine in human trials
On Sept. 28 2020, ViroVax announced that it had licensed its adjuvant, Alhydroxiquim-II, to Bharat Biotech International, an…